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Abstract
Despite signiﬁcant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease
eventually progress after ﬁrst-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor
(TKI) therapy. Understanding existing data on subsequent therapies is crucial to deﬁne an optimal treatment sequence following
ﬁrst-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for
decision-making regarding treatment sequencing beyond ﬁrst-line therapy with VEGFR TKIs.
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Introduction
Signiﬁcant changes in the therapeutic landscape of renal cell
carcinoma (RCC) have drastically improved the outcome of
patients with advanced RCC. Since the approval of high-
dose IL2 (HD IL-2) in the mid-1990s (1, 2), more than
eight new agents with novel mechanisms of action (MOA)
are now available (3). These include seven VEGF inhibitors
(4), two mammalian target of rapamycin (mTOR) inhibitors,
and a novel immune checkpoint inhibitor (5). Despite this
dramatic progress, complete and durable responses to these
agents are rare, and eventual resistance to each agent is
nearly universal.
The endothelial growth factor receptors (VEGFR) tyrosine
kinase inhibitors (TKIs) sunitinib and pazopanib are approved
for the vast majority of patients with untreated advanced
RCC and are the standard of care in this setting (6, 7). Temsir-
olimus, a novel mTOR inhibitor, is the standard of care
for untreated patients with multiple risk factors (poor-risk
group). Drug intolerance and disease progression are the
most common reasons for drug discontinuation, although
the mechanisms of disease resistance are poorly deﬁned.
Unfortunately, despite the advent of the precision medicine
and tumor genomics era, current treatment recommendations
for advanced RCC beyond ﬁrst-line treatment are largely
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driven by generally accepted consensus guidelines, side effect
proﬁles, and quality of life (QOL) interests. Both VEGF and
mTOR inhibition have demonstrated effectiveness in the sec-
ond-line setting and beyond.However, the appropriate patient
phenotype, ideal sequence, timing, and duration of therapy
remain unknown.
In the setting of disease progression on VEGF-directed
therapy, multi-kinase inhibition has become an attractive
therapeutic option with agents such as cabozantinib, a
VEGFR, MET, and AXL inhibitor (8). Similarly, the role
of immunotherapy has also regained momentum with the
recognition that checkpoint inhibition can lead to survival
improvement as demonstrated with the use of the PD1 inhibi-
tor nivolumab in the second-line RCC setting (9). Given a
plethora of treatment options with various MOAs, under-
standing the data from existing trials in the refractory patient
population is crucial to deﬁne the best management for
patients. This review examines the data supporting currently
approved agents in this setting and provides a framework for
decisions regarding sequencing of therapy following ﬁrst-line
VEGF TKI therapy.
Existing Evidence in Second-Line and Beyond
REnal Cell cancer treatment with Oral RAD001
given Daily (RECORD-1)
Everolimus is an oral mTOR inhibitor, a key molecule that
mediates cellular growth, proliferation, cellular metabolism,
andangiogenesis (10). It exerts its functionby inhibiting the intra-
cellular protein FKBP-12 resulting in the inhibition of pS6 and
4EBP1 (11). RECORD-1was a randomized, placebo-controlled
international phase III trial that evaluated the efﬁcacy of evero-
limus or placebo in over 400 patients with advancedRCCwhose
disease had progressed onVEGFRTKIs (12). The vastmajority
of patients had advanced RCC with a clear cell component and
had disease progression on or within 6 months of stopping treat-
ment with either sunitinb or sorafenib or both. Prior therapy
with cytokines or bevacizumab was allowed. Patients were ran-
domized in a 2:1 fashion to receive either everolimus 10 mg
PO or daily placebo. The primary endpoint of this trial was pro-
gression-free survival (PFS) (Table 1). Secondary endpoints
included overall response rate (ORR), safety, overall survival
(OS), disease-related symptoms, and QOL. More than two-
thirds of the patients on study were male and approximately
60% of them had a Karnofsky Performance Status (KPS) of
80%–90%. According to Memorial Sloan Kettering Cancer
Center (MSKCC) risk score (13), more than 85% of patients
in the trial were either good or with intermediate-risk disease.
Although most patients had received one TKI previous to ther-
apy (sunitinb 46% and sorafenib 28%), approximately 26% of
them in both arms had received both oral agents and 9% also
had received the VEGF monoclonal antibody bevacizumab.
PFS assessed by independent central review was signiﬁ-
cantly longer for those receiving everolimus compared to
those on placebo (4.0 vs. 1.9 months, respectively; HR
0.31, 95% CI 0.24–0.41, p < 0.0001). The PFS beneﬁt was
observed and maintained across pre-deﬁned sensitivity and
subgroup analyses. The Response Evaluation Criteria In
Solid Tumors (RECIST)-deﬁned (14) ORR was 1% for ever-
olimus and 0% for placebo; however, a signiﬁcant number of
patients on everolimus (63%) achieved stable disease (SD)
when compared to placebo (32%). The most common
adverse events (AEs) observed on this study were stomatitis,
rash, fatigue, asthenia, and diarrhea. The incidence of grade
(G) 3 and 4 AEs was low. Despite this, treatment with ever-
olimus led to a greater number of G3 and G4 stomatitis,
infections, and non-infectious pneumonitis. Likewise,
laboratory abnormalities including hyperglycemia, hyperch-
olesterolemia, lymphopenia, and hypophosphatemia were
observed more frequently on those patients receiving evero-
limus. Drug discontinuation or secondary drug-related AEs
were observed in 10% of patients on everolimus and
4% on placebo. Similarly, dose modiﬁcations were required
in 34% of patients receiving everolimus versus 15% on
placebo. An updated report of this trial indicated that the
median PFS was 4.9 months (everolimus) versus 1.9 months
(placebo) (hazard ratio [HR], 0.33; P < 0.001) by independent
central review (15). The median OS was 14.8 months (everoli-
mus) versus 14.4 months (placebo) (HR, 0.87; P = 0.162), with
80% of patients in the placebo arm eventually crossed over
to everolimus.
Table 1. Second-line trials (INTORSECT/RECORD 1/AXIS).
Temsirolimus Everolimus Axitinib
MSKCC risk good/int/poor 19/69/12 29/57/15 28/37/33
Comparator Sorafenib Placebo Sorafenib
Endpoint PFS PFS PFS
ORR, % 8 1 19
PFS, months 4.3 4.0 6.7
OS, months 12.3 14.8 20.1
MSKCC, Memorial Sloan Kettering Cancer Center; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
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Axitinib versus sorafenib (AXIS)
The phase III AXIS study evaluated the clinical efﬁcacy and
safety of axitinib versus sorafenib as a second-line therapy
(16). Axitinib is a potent second-generation oral inhibitor of
VEGFR1–3 with a relative potency of 50–450 times greater
than that of the ﬁrst-generation VEGF inhibitors (17).
Another attractive feature of this agent is its lack of off-target
effects and thus a very predictable AE proﬁle (18). The pri-
mary endpoint of AXIS was PFS (Table 1). Secondary end-
points were similar to those of RECORD-1 and included
ORR, safety, and a composite endpoint of duration of response
and time to clinical deterioration. Over 720 patients whose
disease had progressed on one previous systemic therapy
(cytokines, mTOR inhibitors, and VEGF inhibitors with the
exception of axitinib and sorafenib) for RCC were rando-
mized 1:1 to receive either axitinib or sorafenib. Axitinib
was administered as 5 mg PO twice daily (BID), and dose
escalation to 7mg and 10mg POBIDwas allowed for patients
not experiencing G2 AEs. Sorafenib was administered as
400 mg PO BID. Pre-stratiﬁcation according to Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) 0 or 1 and type of previous treatment was also completed.
Among the patients enrolled in the trial, 54% had received
previous therapy with sunitinib, 35% cytokines, 8% bevacizu-
mab, and 3% temsirolimus. Using MSKCC prognostic classi-
ﬁcation (13), 33% of patients were grouped under poor-risk.
The median PFS was 6.7 months for axitinib and 4.7 months
for sorafenib (HR 0.67, 95%CI 0.54–0.81, one-sided p < 0.001).
When evaluating PFS based on previous therapy, for patients
who had received previous cytokine-only therapy, the median
PFS was 12.2 months for axitinib and 8.2 months for sorafenib
(HR 0.51, 95% CI 0.37–0.68, p < 0.0001) (19). The median PFS
for those who had received sunitinib was 6.5 months for axitinib
and 4.4 months for sorafenib (HR 0.72, 95% CI 0.57–0.90,
p = 0.002). The ORR observed for the entire patient population
was 19% for axitinib and 9% for sorafenib. Recently, a post hoc
analysis to determine the efﬁcacy of axitinib and sorafenib based
on response to previous therapy demonstrated that response
to prior therapy does not predict for subsequent response to
either agent (20). This study, however, demonstrated that longer
response to ﬁrst-line therapy generally yields a better outcome
with second-line therapy (20). The most common AEs observed
on axitinib included diarrhea, hypertension (HTN), nausea,
dysphonia, and hypothyroidism. Skin rash, palmar–plantar
erythrodysesthesia (PPE), and alopecia were more common
with sorafenib therapy. Similarly, the most common G3 and
G4 AEs reported include HTN, diarrhea and fatigue with
axitinib and PPE, hypophosphatemia, elevated lipase, andHTN
with sorafenib.
Recently, Motzer et al. (19) reported the analysis on PFS and
OS from this study. The median OS was 20.1 months with
axitinib and 19.2 months with sorafenib (HR 0.97, 95%
CI 0.80–1.17, p = 0.3744). Similarly, the median investigator-
assessed PFS was 8.3 months for axitinib and 5.7 months for
sorafenib (HR 0.66, 95% CI 0.55–0.78, p < 0.0001). HTN
was identiﬁed as a prognostic factor for survival in patients trea-
ted with axitinib (20.7 vs. 12.9 months, p = 0.012) and sorafenib
(20.2 vs. 14.8 months, p = 0.002). In this updated analysis,
AEs were similar to those reported initially.
Investigating Torisel as second-line therapy
(INTORSECT)
Although temsirolimus has been approved as ﬁrst-line treat-
ment for untreated advanced RCC patients with multiple
risk factors based on the OS beneﬁt reported in the global
AARC trial (21), its clinical efﬁcacy in the second-line setting
was evaluated in the INTORSECT trial, a randomized inter-
national open-label, multicenter phase III study evaluating
sorafenib and temsirolimus in patients whose disease pro-
gressed on sunitinib (Table 1) (22). A total of 512 eligible
patients had histologically conﬁrmed advanced RCC (any
histology) with RECIST-deﬁned (14) disease progression
while receiving ﬁrst-line therapy with sunitinib. All patients
must have previously received at least 4 weeks of sunitinib-
based therapy independent of dose or schema. Although
patients with clinical progression were allowed to participate
in the study, those who discontinued sunitinib secondary to
AEs were not allowed to participate. Enrolled patients were
randomized 1:1 and received either intravenous (IV) temsiro-
limus 25 mg once weekly or oral sorafenib 400 mg twice
per day. Patients were stratiﬁed based on the standard disease
features for advanced RCC studies. The primary endpoint
was PFS with secondary endpoints that included ORR, OS,
and safety. With a median follow-up of 9.2 months, the
median PFS was 4.3 months for temsirolimus and 3.9 months
for sorafenib (HR: 0.87; 95% CI 0.71–1.07; two-sided
p = 0.19). The conﬁrmed independent review ORR was
8% and this was similar in both arms. The median OS was
signiﬁcantly longer with temsirolimus than with sorafenib
with 12.3 versus 16.6 months, respectively (HR1.31; 95%
CI 1.05–1.63; two-sided p = 0.01). No new safety signals of
concern were identiﬁed. In fact, the same proportion of
patients experienced at least one G3 AE (70% with temsiroli-
mus and 69% with sorafenib). G3 anemia and hyperglycemia
were more common with temsirolimus (9% vs. 3% and 8% vs.
2%, respectively). Similarly, G3 PPE was more frequent with
sorafenib (0% vs. 15%). AEs resulting in dose reductions were
observed in 16% of the patients receiving temsirolimus and
33% on sorafenib, respectively. Although the lack of correla-
tion between PFS and OS in this trial is not well understood,
INTORSECT was the ﬁrst study in the second-line setting
demonstrating an OS beneﬁt for patients with advanced
RCC. The results, however, do not suggest that sorafenib is
the second-line agent of choice, rather solidiﬁed the hypoth-
esis that angiogenic escape is in fact one of the mechanisms
resistant to ﬁrst-line VEGFR inhibition, and thus, the possi-
bility that sequential VEGF-based therapy is a logical treat-
ment strategy in patients with advanced RCC.
Barata PC et al.
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Global oncologic leanings for dovitinib (GOLD)
Dovitinib is an oral TKI that inhibits FGF receptor (FGFR),
VEGFR, and PDGFR. In preclinical studies, this agent
demonstrated greater antitumor activity when compared
to sunitinib and sorafenib (23, 24). Dovitinib has also
shown antitumor activity with reported PFS of approxi-
mately 5 months in early-phase clinical trials in patients pre-
viously treated with VEGF and mTOR inhibitors. For the
same setting, median PFS of patients treated with sorafenib
ranged between 3.4 and 4.4 months, in different phase II
studies (16, 25, 26).
In the phase IIIGOLD trial, 284 patientswithmetastatic clear
cell RCC who received one previous VEGF-targeted therapy
and one previous mTOR inhibitor were randomized to receive
either dovitinib 500 mg orally 5-days-on and 2-days-off or sora-
fenib 400 mg orally twice daily (27). Patients were also stratiﬁed
based on the standard disease features for advanced RCC
studies. With a median follow-up of 11.3 months, there was no
difference in the mPFS between both arms (3.7 and 3.6 months
for dovinitib and sorafenib groups, respectively; HR 0.86,
95% CI 0.72–1.04; one-sided p = 0.063).
Most common G3/G4 AEs included hypertriglyceridemia
(14%), fatigue (10%), HTN (8%), and diarrhea (7%) in the
dovitinib group, and HTN (17%), fatigue (8%), dyspnea
(7%), and PPE (6%) in the sorafenib group. Percentage of
patients who discontinued dovitinib and sorafenib due to
AEs is 15% and 12%, respectively. Despite the good tolerabil-
ity, dovitinib failed to meet the primary endpoint of PFS
versus sorafenib in patients pretreated and progressive
RCC, and, consequently, has not been approved by FDA
for the treatment of advanced RCC.
Recently approved agents
Cabozantinib
Cabozantinib is an oral TKI of MET, VEGFRs, and AXL
initially tested in a single–arm, phase I study of advanced
RCC patients resistant to VEGF and mTOR inhibitors (28)
that has now entered the armamentarium of agents for
patients with TKI refractory disease. METEOR was a rando-
mized open-label, phase III trial of cabozantinib versus ever-
olimus in advanced RCC patients with progressive disease
after VEGFR TKI therapy (Table 2) (29). There was no
limit as to the number of prior therapies although the majority
of patients (73%) had received only one prior therapy, suniti-
nib being themost common.All randomized patients (n= 658)
received either cabozantinib at 60 mg PO once daily or evero-
limus at 10 mg daily. The primary endpoint of the trials was
PFS. ORR, survival, and safety were secondary endpoints.
Similar to other second-line studies, all patients were stratiﬁed
based on validated risk factor criteria in advanced RCC. The
estimated median PFS for patients receiving cabozantinib
was 7.4 months compared to 3.8 months for those receiving
everolimus. TheHR for progression of death while on therapy
was higher in the everolimus-treated population (HR 0.58;
95% CI 0.45 to 0.75; P < 0.001). The PFS beneﬁt observed
with cabozantinib was observed independent of MSKCC
risk-group or ﬁrst-line treatment received. The ORR was
higher in those receiving cabozantinib (21%) compared to
those on everolimus (5%) (P < 0.001). More recently, the
ﬁnal OS results were published (30). The median OS was
21.4 months for patients treated with cabozantinib compared
with 16.5months for those who received everolimus (HR 0.66,
95% CI 0.53–0.83, P < 0·001).
Although others have been using this agent in thyroid can-
cer with no signiﬁcant safety concerns (31), it is important
to point out the safety proﬁle observed on this study. Dose
reductions were almost three times more common with
cabozantinib compared with everolimus (60% vs. 25%,
respectively). In both groups, approximately 10% of patients
discontinued therapy due to drug intolerance, and the inci-
dence of >G3 AEs was similar for both drugs (68% and
58%, respectively). Although HTN, diarrhea, and fatigue
were the most common G3 AEs observed with cabozantinib,
the most common G3 AEs reported with everolimus included
anemia, fatigue, and hyperglycemia. Cabozantinib 60 mg per
day eventually gained FDA approval in April 2016 and has
become a standard of care in the second-line setting (8).
Table 2. Second-line trials (METEOR/CheckMate 025/Lenvatinib–Everolimus).
Cabozantinib Nivolumab Lenvatinib–Everolimus
MSKCC risk good/int/poor 45/42/12 35/49/16 24/37/39
Comparator Everolimus Everolimus Everolimus
Endpoint PFS OS PFS
ORR, % 17 22 35
PFS, months 7.4 4.6 12.8
OS, months 21.4 25.0 25.5
MSKCC, Memorial Sloan Kettering Cancer Center; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
Sequential therapy in Advanced RCC: Evidence-based Practice
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Nivolumab
Recent ﬁndings have demonstrated the importance of
the programmed cell-death protein 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) pathways in
immune surveillance. This had led to the rapid development
of agents capable of blocking these targets. A number
of checkpoint inhibitors including ipilumumab (CTLA-4
inhibitor), atezolizumab (programmed death ligand 1 [PD-
L1] inhibitor), and nivolumab and pembrolizumab (PD-1
inhibitors) have been approved for a variety of cancers.
These antibodies block PD1 or its ligand PD-L1. Although
atezolizumab and pembrolizumab are undergoing clinical
development in RCC, nivolumab is the only PD1 inhibitor
currently FDA approved in the VEGF TKI refractory
RCC space. Nivolumab is a fully human IgG4 PD1 immune
checkpoint inhibitor that selectively blocks PD1 expressed in
T cells and PD-L1 and PD-L2 expressed in tumor cells and
other immune cells (32).
CheckMate-025, a phase III study, compared nivolumab to
everolimus in patients with VEGF TKI refractory advanced
RCC (Table 2) (9). A total of 821 patients previously treated
with one (72%) or two (28%) antiangiogenic drugs were ran-
domized to receive 3 mg/kg IV once every 3 weeks or 10 mg
everolimus orally once daily. The primary endpoint was OS,
and secondary endpoints included ORR, PFS, and correla-
tion of OS with expression of PD-L1. The median OS was
25.0 months with nivolumab and 19.6 months with everoli-
mus (HR 0.73, 98.5% CI 0.57–0.93; P = 0.002). The ORR
was also greater with nivolumab than with everolimus (25%
vs. 5%; P = 0.002) but median PFS was similar between the
two groups. A subset analysis of the 756 (92%) patients
with quantiﬁable tumor PD-L1 expression showed a signiﬁ-
cantly higher OS for patients treated with nivolumab, regard-
less of baseline factors, PD-L1 status, and number of prior
therapies (33).
Nivolumab was also generally better tolerated than evero-
limus. G3/G4 treatment-related AEs occurred in 19% of the
patients receiving nivolumab and in 37% of the patients
receiving everolimus. The most common AE with nivolumab
was fatigue (in 2%), whereas the most common AE with ever-
olimus was anemia (in 8%). Furthermore, nivolumab was
also associated with improved QOL compared with everoli-
mus (34). Based on the survival beneﬁt and favorable toxicity
proﬁle, the FDA approved nivolumab in November 2015 for
the treatment of patients with advanced RCC who have
received prior anti-angiogenic therapy (35).
Lenvatinib–everolimus combination
Recognizing the importance of VEGFR and mTOR pathways
in RCC, a synergistic effect with dual inhibition has been sug-
gested in preclinical and phase I and II studies (36). A recent
phase II clinical trial studied this combination of the mTORi
everolimus with lenvatinib, an inhibitor of VEGFR1–3,
Fibroblast Growth Factor Receptor 1–4 (FGFR1–4), Platelet
Derived Growth Factor Receptor alpha (PDGFRa), RET,
and KIT (Table 2) (37, 38). In this study,Motzer and colleagues
randomized 153 patients to receive single-agent lenvatinib 24mg
(n = 52), single-agent everolimus 10 mg (n = 50), or the combi-
nation of both agents 18 mg/5 mg (n = 51) (39). The primary
endpoint was PFS. Patients were stratiﬁed by two factors: hemo-
globin (men, ≤130 g/L and >130 g/L; women, ≤115 g/L and
>115 g/L) and corrected serum calcium (≥2.5 mmol/L and
<2.5 mmol/L).
Patients allocated to lenvatinib plus everolimus were treated
for a median of 7.6 months, compared with 7.4 months for
those assigned to single-agent lenvatinib and 4.1 months for
those who received single-agent everolimus. Median PFS
was 14.6 months for lenvatinib plus everolimus and 5.5 months
for single-agent everolimus (HR 0.40, 95% CI 0·24–0.68;
P < 0.001). Patients treated with single-agent lenvatinib had a
median PFS of 7.4 months, which was also longer compared
with those treated with single-agent everolimus (HR 0.61, 95%
CI 0.38–0.98; P = 0.048). In an updated OS analysis, the median
was 25.5 months for lenvatinib/everolimus, compared with
15.4 months for patients treated with everolimus (HR 0.59,
95% CI 0.36–0.96, P = 0.065), which demonstrated a trend
towards survival beneﬁt with the experimental combination
(40). Overall, ORR was achieved by 43% of the patients allo-
cated combination regimen compared with 27% assigned lenva-
tinib (ORR 1.6, 95% CI 0.9–2.8; P = 0.10) and 6%who received
everolimus (ORR 7.2, 95% CI 2.3–22.5; P < 0.001).
Equally important were the results addressing the safety
proﬁle of these drugs. In this study, the most common signif-
icant (G3/G4) treatment-related AEs in patients allocated
lenvatinib plus everolimus were diarrhea (20%), proteinuria
(19%) in those assigned to single-agent lenvatinib, and ane-
mia (12%) in those assigned to single-agent everolimus. Con-
sequently, discontinuation rate secondary to AEs was 24%
for patients treated with the combination regimen and sin-
gle-agent lenvatinib, compared with 7% for patients treated
with everolimus. Two deaths were possibly related to study
drug, one cerebral hemorrhage in the lenvatinib plus everoli-
mus group and one myocardial infarction with single-agent
lenvatinib.
Of note, there is no randomized phase III study conﬁrming
the results of this study. Therefore, limitations such as popu-
lation selection and false-positive rates may had originated
biased results (41, 42). Nonetheless, based on the positive
results from this phase II study, the combination of lenvatinib
and everolimus was recently approved by FDA (May 2016)
for the treatment of patients with advanced RCC pretreated
with one anti-VEGF therapy (43). A dose ﬁnding trial com-
paring the approved combination dose of lenvatinib and ever-
olimus 18 mg/5 mg with 14 mg/5 mg was mandated by FDA
to ﬁgure out what is the best combination dose. This trial is
planned to open soon.
Barata PC et al.
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Discussion
Metastatic RCC (mRCC) has gained a variety of thera-
peutic options since the approval of the ﬁrst VEGF TKI in
the mid-2000s. Most recently, the treatment landscape for
advanced RCC has drastically changed with results from
three randomized clinical trials leading to the approval of
nivolumab, cabozantinib, and the combination of lenvati-
nib/everolimus in previously treated advanced RCC (44).
However, as no head-to-head trials exist, physicians are
faced with the challenge of choosing the appropriate therapy
for an individual patient. As such, clinical decisions are fre-
quently made based on multiple factors including patient
comorbidities, disease characteristics, known drug toxici-
ties, and physician experience with different drugs.
Because RCC has joined the list of tumors where immune
checkpoint inhibitors have shown to signiﬁcantly improve
OS and the possibility of long-term disease control for a
subgroup of patients is real, the favorable side effect proﬁle
of these agents makes them a particularly appealing option.
In opposition to other drugs, the majority of patients will
develop minimal side effects; therefore, nivolumab may be
considered for more fragile patients with lower performance
status, multiple comorbidities, and organ dysfunction, including
renal impairment, otherwise ineligible or borderline eligible for
other therapies (45).
Acknowledging that only a subgroup of patients poten-
tially beneﬁts from this class of agents and the absence of a
reliable biomarker to help us selecting those patients, one of
the questions that will need to be answered is the optimal tim-
ing of immunotherapy in RCC. Since its approval, most
patients receive nivolumab as second-line agent with the
expectation of an improved QOL and the possibility of a
long-lasting response to therapy.
Based on Checkmate 025, where patients had received up
to three previous antiangiogenic therapies, approximately
one-third of the patients were treated in third-line setting, sug-
gesting a beneﬁt later in the course of the disease. On the con-
trary, multiple clinical trials are ongoing, studying nivolumab
and other checkpoint inhibitors in ﬁrst-line setting, as single
agents or in combination with VEGF inhibitors. We antici-
pate that the results of these studies may help answering
this question of best timing for this class of agents (44, 46–48).
Cabozantinib and lenvatinib/everolimus may be two
attractive options to consider for patients with rapidly pro-
gressive disease or those who are primary refractory to
VEGFR TKI-based therapy. Both agents can lead to cytore-
duction with more than 80% of patients achieving clinical
Partial Response (cPRs) or SD with tumor burden reduction,
regardless of performance status, number of prior lines, and
metastatic sites (visceral vs. bones) (29, 40, 49, 50). For
patients with treated brain metastasis, cabozantinib may
also be considered an effective option. Contrary to Check-
mate 025 and Len/Eve studies, this subgroup of patients
was allowed in the METEOR phase III trial. From a logisti-
cal perspective, both cabozantinib and lenvatinib/everolimus
are oral therapies and do not require frequent clinic visits for
drug administration as required for those receiving nivolu-
mab. Conversely, their toxicity proﬁle constitutes an impor-
tant limitation for many patients, especially those heavily
pretreated. Approximately 10% of patients discontinued
cabozantinib due to drug intolerance, and two thirds reported
an incidence of >G3 AEs, whereas most patients receiving
envatinib/everolimus (89%) reported signiﬁcant AEs that
led to dose reductions or interruptions. Similarly, nearly
20% had signiﬁcant diarrhea, which led FDA to include a
special warning on the drug’s label about the risk of this
AE and mandated the investigation team to conduct a
dose-ﬁnding study with an alternative dose combination
(43). To overcome the limitation of toxicity with cabozantinib,
there is the option to reduce the dose to 40 mg or even 20 mg
per day, as allowed by the research protocol. Many physicians
therefore avoid treatment with the approved dose of 60 mg
daily and instead treat patients at lower doses, though the
loss of efﬁcacy at these doses is not completely known.
Beyond the newer agents of nivolumab and cabozantinib,
treatment with axitinib remains a less attractive but valid
option in the second-line setting particularly with the use of
individualized dose titration, which may help to potentiate
its clinical beneﬁt (51).
Finally, the role of monotherapy withmTOR inhibitors has
become less popular in advanced RCC and should be reserved
for patients with molecular genotypes that would predict
response to mTOR-based therapy (i.e. TSC1/2 mutations).
Despite the array of approved drugs based on randomized
trials, there are still no good data on sequencing strategies to
support the use of a particular agent in the second and addi-
tional lines of therapy. Similarly, the multiple biomarker can-
didates from plasma, tumor, and host tissues have failed to
identify patients more likely to respond to these therapies
(52). PD-L1 and MET staining in both METEOR and
Checkmate 025 trials are examples of these challenges (9, 30).
In the absence of biomarkers that can predict response to
existing agents, most physicians will deﬁne their second- and
third-line therapy based on tolerability, AEs, QOL, and survi-
val beneﬁt. Based on randomized phase III data, nivolumab
and cabozantinib are likely be the two agents of choice in
these clinical scenarios. Nivolumab is a much more attractive
option after TKI-based therapy when one looks at its AEs and
compared those to the ones reported in the METEOR study.
It is also mechanistically different to TKI-based therapy,
and its broad utilization and activity across other solid
tumors makes it a very attractive treatment alternative in
the second-line setting after pazopanib- or sunitinib-based
therapy. Others might feel that a rapid response is required
especially for those patients who are primary refractory to
ﬁrst-line VEGFR TKI therapy. In this case, it is fair to say
that cabozantinib can lead to rapid responses, often in less
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than 60 days. Main issues, however, remain tolerability as
most patients do require dose reductions within the same
time frame of 60 days. Although the misconception that
checkpoint inhibitors cannot lead to rapid response remains,
it is important to note that the median response to nivolumab
in Checkmate 025 was 3.5 months. Similarly, best response at
4 months appears to predict for OS beneﬁt as demonstrated in
the subset analysis by Motzer et al. (33). As for the combina-
tion of lenvatinib/everolimus, the randomized phase II design
of the study coupled with concerns for AEs and the logistical
complexity of using two different agents at the same time
have made it a less attractive therapeutic option in the second-
or third-line space. In summary, patients with progressive
disease after ﬁrst-line VEGFR TKIs will go on to receive
a checkpoint inhibitor making cabozantinib a third-line
agent for the vast majority of RCC patients not eligible for
clinical trials.
Conclusion
With the introduction of different options in the VEGFR
TKI refractory setting, choosing the ideal therapy remains a
biologic and therapeutic challenge. There are currently no
predictive biomarkers that determine the best therapy for
the right patient, and little is known about the best sequence
of treatments. Future clinical trials with drug combinations,
predictive biomarkers, and novel therapeutics will hopefully
help resolving some of these challenges.
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